Andrew V Biankin

List of Publications by Year in Descending Order

172 papers	26,947 citations	62 h-index	164 g-index
185 ext. papers	33,018 ext. citations	11.3 avg, IF	6.12 L-index

#	Paper	IF	Citations
172	ICGC-ARGO precision medicine: familial matters in pancreatic cancer.. *Lancet Oncology, The*, **2022**, 23, 25-26	21.7	2
171	ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer.. *Lancet Oncology, The*, **2022**, 23, 463-464	21.7	0
170	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. *Nature Communications*, **2021**, 12, 6738	17.4	1
169	ROR1 and ROR2 expression in pancreatic cancer. *BMC Cancer*, **2021**, 21, 1199	4.8	0
168	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. *Cancer Cell*, **2021**, 39, 1497-1518.e11	24.3	14
167	Structural Variants at the Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. *Clinical Cancer Research*, **2021**, 27, 3201-3214	12.9	1
166	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. *Gastroenterology*, **2021**, 160, 362-377.e13	13.3	32
165	Molecular Subtyping of Pancreatic Cancer **2021**, 305-319		
164	DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. *Communications Biology*, **2021**, 4, 155	6.7	11
163	Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. *Cancers*, **2021**, 13,	6.6	2
162	Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. *Journal of Clinical Oncology*, **2021**, 39, 2617-2631	2.2	15
161	Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. *Gastroenterology*, **2021**, 161, 1758-1763	13.3	2
160	Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. *Seminars in Cancer Biology*, **2021**,	12.7	3
159	Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. *Gastroenterology*, **2021**,	13.3	1
158	COVID-19 provides an opportunity to transform cancer research. *Cancer Cell*, **2021**, 39, 1169-1170	24.3	0
157	Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. *Science Advances*, **2021**, 7, eabh0363	14.3	5
156	FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs. *Scientific Reports*, **2021**, 11, 229	4.9	3

155	Molecular Subtyping and Precision Medicine for Pancreatic Cancer. *Journal of Clinical Medicine*, **2021**, 10,	5.1	10
154	Defining the clinical genomic landscape for real-world precision oncology. *Genomics*, **2020**, 112, 5324-5330	4.3	4
153	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. *Cell Reports*, **2020**, 31, 107625	10.6	34
152	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. *Cancer Cell*, **2020**, 38, 198-211.e8	24.3	38
151	An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. *Molecular Oncology*, **2020**, 14, 1800-1816	7.9	4
150	Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma. *Cancer Discovery*, **2020**, 10, 872-887	24.4	42
149	Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. *Annals of Surgery*, **2020**, 272, 366-376	7.8	24
148	Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis. *Cancer Cell*, **2019**, 36, 319-336.e7	24.3	135
147	Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. *Cancer Research*, **2019**, 79, 5316-5327	10.1	19
146	Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. *Chinese Clinical Oncology*, **2019**, 8, 16	2.3	15
145	Molecular subtypes of pancreatic cancer. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 207-220	24.2	281
144	Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. *Cell Metabolism*, **2019**, 29, 1390-1399.e6	24.6	164
143	CSF1R Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. *Cell Reports*, **2018**, 23, 1448-1460	10.6	105
142	Chemotherapy and radiotherapy for advanced pancreatic cancer. *The Cochrane Library*, **2018**, 3, CD011044	5.2	48
141	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. *Gut*, **2018**, 67, 2142-2155	19.2	71
140	Exome-Wide Association Study of Pancreatic Cancer Risk. *Gastroenterology*, **2018**, 154, 719-722.e3	13.3	27
139	Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious Mutation. *JCO Precision Oncology*, **2018**, 2018,	3.6	78
138	10. Precision Oncology in Surgery: Patient Selection Biomarkers for Operable Pancreatic Cancer. *European Journal of Surgical Oncology*, **2018**, 44, 1838	3.6	5

137	Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. *Oncotarget*, **2018**, 9, 21613-21627	3.3	29
136	ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling. *Nature Communications*, **2018**, 9, 5083	17.4	29
135	Interrogating open issues in cancer precision medicine with patient-derived xenografts. *Nature Reviews Cancer*, **2017**, 17, 254-268	31.3	369
134	An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. *Nature Communications*, **2017**, 8, 14294	17.4	73
133	The road to precision oncology. *Nature Genetics*, **2017**, 49, 320-321	36.3	10
132	GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. *Gut*, **2017**, 66, 1665-1676	19.2	125
131	Whole-genome landscape of pancreatic neuroendocrine tumours. *Nature*, **2017**, 543, 65-71	50.4	482
130	Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. *Nature Genetics*, **2017**, 49, 825-833	36.3	41
129	Mitochondrial mutations and metabolic adaptation in pancreatic cancer. *Cancer & Metabolism*, **2017**, 5, 2	5.4	40
128	Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. *Science Translational Medicine*, **2017**, 9,	17.5	159
127	Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. *Clinical Cancer Research*, **2017**, 23, 1638-1646	12.9	92
126	BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. *British Journal of Cancer*, **2017**, 116, 1021-1026	8.7	48
125	The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. *Clinical Cancer Research*, **2017**, 23, 7633-7640	12.9	13
124	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. *Cancer Cell*, **2017**, 32, 185-203.e13	24.5	896
123	Lost in translation: returning germline genetic results in genome-scale cancer research. *Genome Medicine*, **2017**, 9, 41	14.4	18
122	Hypermutation In Pancreatic Cancer. *Gastroenterology*, **2017**, 152, 68-74.e2	13.3	130
121	MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. *Oncotarget*, **2017**, 8, 9216-9229	3.3	9
120	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. *Scientific Reports*, **2016**, 6, 35848	4.9	87

119	Pancreatic cancer. *Nature Reviews Disease Primers*, **2016**, 2, 16022	51.1	838
118	Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. *Molecular and Cellular Proteomics*, **2016**, 15, 2671-85	7.6	25
117	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. *Cancer Cell*, **2016**, 29, 832-845	24.3	442
116	Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. *British Journal of Cancer*, **2016**, 114, 269-80	8.7	66
115	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. *Cell Reports*, **2016**, 14, 907-919	10.6	75
114	Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature*, **2016**, 531, 47-52	50.4	1785
113	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. *Pancreatology*, **2016**, 16, 14-27	3.8	49
112	Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions. *Oncotarget*, **2016**, 7, 74768-74778	3.3	17
111	Molecular Diagnostics: Translation from Discovery to Clinical Practice **2016**, 1-26		
110	PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. *Genes and Development*, **2016**, 30, 2669-2683	12.6	62
109	Diagnosis and Management of Hereditary Pancreatic Cancer. *Recent Results in Cancer Research*, **2016**, 205, 61-83	1.5	1
108	Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature*, **2015**, 518, 495-501	50.4	1579
107	New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. *Journal of Clinical Oncology*, **2015**, 33, e52-6	2.2	25
106	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. *Clinical Cancer Research*, **2015**, 21, 2029-37	12.9	171
105	The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. *Molecular Cancer*, **2015**, 14, 139	42.1	29
104	Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. *Critical Reviews in Oncology/Hematology*, **2015**, 96, 483-97	7	32
103	Subtyping Pancreatic Cancer. *Cancer Cell*, **2015**, 28, 411-413	24.3	31
102	Patient-centric trials for therapeutic development in precision oncology. *Nature*, **2015**, 526, 361-70	50.4	199

101	Cancer Genetics and Implications for Clinical Management. *Surgical Clinics of North America*, **2015**, 95, 919-34	4	5
100	SOX9 regulates ERBB signalling in pancreatic cancer development. *Gut*, **2015**, 64, 1790-9	19.2	57
99	Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. *Expert Reviews in Molecular Medicine*, **2015**, 17, e17	6.7	33
98	A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. *American Journal of Surgical Pathology*, **2015**, 39, 1730-41	6.7	423
97	Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. *EMBO Molecular Medicine*, **2015** , 7, 1063-76	12	172
96	Pancreas-Specific Sirt1-Deficiency in Mice Compromises Beta-Cell Function without Development of Hyperglycemia. *PLoS ONE*, **2015**, 10, e0128012	3.7	19
95	The epigenetic agents suberoylanilide hydroxamic acid and 5-AZA-2Sdeoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. *International Journal of Oncology*, **2015**, 46, 2223-30	4.4	14
94	The Challenges of Precision Oncology Drug Development and Implementation. *Public Health Genomics*, **2015**, 18, 338-48	1.9	13
93	Pancreatic cancer genomics: where can the science take us?. *Clinical Genetics*, **2015**, 88, 213-9	4	10
92	II-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. *Oncotarget*, **2015**, 6, 2235-49	3.3	48
91	Mining the genomes of exceptional responders. *Nature Reviews Cancer*, **2014**, 14, 291-2	31.3	35
90	Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor signaling. *Cell*, **2014**, 157, 382-394	56.2	325
89	Patient-derived xenograft models: an emerging platform for translational cancer research. *Cancer Discovery*, **2014**, 4, 998-1013	24.4	1018
88	Returning individual research results for genome sequences of pancreatic cancer. *Genome Medicine* , **2014**, 6, 42	14.4	18
87	Pancreatic cancer genomics. *Current Opinion in Genetics and Development*, **2014**, 24, 74-81	4.9	40
86	A workflow to increase verification rate of chromosomal structural rearrangements using high-throughput next-generation sequencing. *BioTechniques*, **2014**, 57, 31-8	2.5	
85	Stratified Medicine for Pancreatic Cancer **2014**, 807-814		
84	Clinical and pathologic features of familial pancreatic cancer. *Cancer*, **2014**, 120, 3669-75	6.4	38

83	Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. *International Journal of Cancer*, **2014**, 135, 1110-8	7.5	149
82	Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. *Cancer Research*, **2014**, 74, 6390-6396	10.1	26
81	Targeting mTOR dependency in pancreatic cancer. *Gut*, **2014**, 63, 1481-9	19.2	93
80	Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. *Clinical Cancer Research*, **2014**, 20, 3187-97	12.9	30
79	Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. *Oncotarget*, **2014**, 5, 4257-68	3.3	24
78	Personalising pancreas cancer treatment: When tissue is the issue. *World Journal of Gastroenterology*, **2014**, 20, 7849-63	5.6	18
77	Understanding pancreatic cancer genomes. *Journal of Hepato-Biliary-Pancreatic Sciences*, **2013**, 20, 549-56	2.8	26
76	Signatures of mutational processes in human cancer. *Nature*, **2013**, 500, 415-21	50.4	5895
75	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. *Genome Medicine*, **2013**, 5, 78	14.4	82
74	Novel cancer drivers: mining the kinome. *Genome Medicine*, **2013**, 5, 19	14.4	2
73	Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. *Journal of Clinical Oncology*, **2013**, 31, 1348-56	2.2	112
72	Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial β integrin. *Cancer Research*, **2013**, 73, 4579-4590	10.1	65
71	BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. *Molecular Cancer Therapeutics*, **2013**, 12, 1874-85	6.1	36
70	Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer. *Cancer Research*, **2013**, 73, 2357-67	10.1	48
69	Reply to G.F. Arroyo. *Journal of Clinical Oncology*, **2013**, 31, 3843-4	2.2	
68	Somatic point mutation calling in low cellularity tumors. *PLoS ONE*, **2013**, 8, e74380	3.7	49
67	Molecular pathways in colorectal cancer. *Journal of Gastroenterology and Hepatology (Australia)*, **2012**, 27, 1423-31	4	151
66	Factors influencing intention to undergo whole genome screening in future healthcare: a single-blind parallel-group randomised trial. *Preventive Medicine*, **2012**, 55, 514-20	4.3	62

65	RON is not a prognostic marker for resectable pancreatic cancer. *BMC Cancer*, **2012**, 12, 395	4.8	16
64	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature*, **2012**, 491, 399-405	50.4	1427
63	PINA v2.0: mining interactome modules. *Nucleic Acids Research*, **2012**, 40, D862-5	20.1	267
62	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. *Nature*, **2012**, 486, 266-70	50.4	253
61	Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 5934-41	11.5	179
60	qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. *PLoS ONE*, **2012**, 7, e45835	3.7	80
59	Adult cardiac-resident MSC-like stem cells with a proepicardial origin. *Cell Stem Cell*, **2011**, 9, 527-40	18	313
58	Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. *PLoS ONE*, **2011**, 6, e26088	3.7	48
57	Retinoid signaling in pancreatic cancer, injury and regeneration. *PLoS ONE*, **2011**, 6, e29075	3.7	12
56	Precursor lesions in pancreatic cancer: morphological and molecular pathology. *Pathology*, **2011**, 43, 183-200	1.6	48
55	Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. *Journal of Gastroenterology and Hepatology (Australia)*, **2011**, 26, 267-74	4	43
54	LMO4 expression in squamous cell carcinoma of the anterior tongue. *Histopathology*, **2011**, 58, 477-80	7.3	8
53	Long term nutritional status and quality of life following major upper gastrointestinal surgery - a cross-sectional study. *Clinical Nutrition*, **2011**, 30, 774-9	5.9	45
52	Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. *Human Genetics*, **2011**, 130, 93-101	6.3	12
51	Somatic variation and cancer: therapies lost in the mix. *Human Genetics*, **2011**, 130, 79-91	6.3	34
50	SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. *PLoS Genetics*, **2011**, 7, e1002135	6	117
49	International network of cancer genome projects. *Nature*, **2010**, 464, 993-8	50.4	1613
48	Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. *Cancer Research*, **2010**, 70, 9391-401	10.1	143

47	Plexiform angiomyxoid myofibroblastic tumour of the stomach: a case report. *Pathology*, **2010**, 42, 581-3	1.6	14
46	Role of pancreatic stellate cells in pancreatic cancer metastasis. *American Journal of Pathology*, **2010**, 177, 2585-96	5.8	257
45	Defining research priorities for pancreatic cancer in Australia: results of a consensus development process. *Cancer Causes and Control*, **2010**, 21, 729-36	2.8	19
44	Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. *International Journal of Cancer*, **2010**, 126, 1445-53	7.5	11
43	Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. *Journal of Clinical Investigation*, **2010**, 120, 2171-83	15.9	154
42	Synoptic reporting improves histopathological assessment of pancreatic resection specimens. *Pathology*, **2009**, 41, 161-7	1.6	79
41	Margin clearance and outcome in resected pancreatic cancer. *Journal of Clinical Oncology*, **2009**, 27, 2855-62	2.6	241
40	Surgical therapy for gastrointestinal stromal tumours of the upper gastrointestinal tract. *Journal of Gastrointestinal Surgery*, **2009**, 13, 1220-5	3.3	21
39	Taking optical biopsies with confocal endomicroscopy. *Journal of Gastroenterology and Hepatology (Australia)*, **2009**, 24, 1701-3	4	4
38	Giant inguinal hernia containing right colon repaired using the prolene hernia system. *ANZ Journal of Surgery*, **2009**, 79, 92-3	1	2
37	Role of endoscopic ultrasound in pancreatic cancer. *Expert Review of Gastroenterology and Hepatology*, **2009**, 3, 293-303	4.2	8
36	Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. *Gastroenterology*, **2009**, 137, 558-68, 568.e1-11	13.3	62
35	Real time intraoperative confocal laser microscopy-guided surgery. *Annals of Surgery*, **2009**, 249, 735-7	7.8	22
34	Abdominal shotgun wound with pellet embolization leading to bilateral lower limb amputation: case report and review of the literature of missile emboli over the past 10 years. *Journal of Trauma*, **2009**, 67, E202-8		11
33	Messina: a novel analysis tool to identify biologically relevant molecules in disease. *PLoS ONE*, **2009**, 4, e5337	3.7	5
32	Management of Nutritional Issues After Major Pancreatic Resections **2009**, 487-506		
31	Improving outcomes for operable pancreatic cancer: is access to safer surgery the problem?. *Journal of Gastroenterology and Hepatology (Australia)*, **2008**, 23, 1036-45	4	25
30	Individualizing therapy for pancreatic cancer. *Journal of Gastroenterology and Hepatology (Australia)*, **2008**, 23, 1779-82	4	5

29	Role of endoscopic ultrasound in the management of pancreatic lesions. *ANZ Journal of Surgery*, **2008**, 78, 315-6; author reply 316-7	1	1
28	Stabilization of beta-catenin induces pancreas tumor formation. *Gastroenterology*, **2008**, 135, 1288-300	13.3	126
27	In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. *Gastroenterology*, **2008**, 135, 1870-6	13.3	86
26	The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome. *Breast Cancer Research*, **2008**, 10, R28	8.3	24
25	Pancreatic anomaly with multiple endocrine neoplasia type 1: a case of pancreas divisum and hemosuccus pancreaticus (santorinirrhage). *Pancreas*, **2008**, 36, 314-5	2.6	4
24	Pathology and Molecular Biology of Intraductal Papillary Mucinous Neoplasms **2008**, 53-64		
23	Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. *PLoS ONE*, **2007**, 2, e1155	3.7	182
22	Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. *Journal of Clinical Pathology*, **2007**, 60, 622-6	3.9	16
21	A histological survey of green fluorescent protein expression in SgreenSmice: implications for stem cell research. *Pathology*, **2007**, 39, 247-51	1.6	14
20	A novel approach to high definition, high-contrast video capture in abdominal surgery. *Annals of Surgery*, **2007**, 245, 533-5	7.8	29
19	Cyclin E expression and outcome in pancreatic ductal adenocarcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 1941-7	4	22
18	Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 711-6	4	53
17	Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. *Cancer Research*, **2006**, 66, 95-106	10.1	357
16	Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. *Journal of the National Cancer Institute*, **2006**, 98, 1420-4	9.7	76
15	Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. *Journal of Clinical Oncology*, **2005**, 23, 1811-8	2.2	46
14	Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. *Cancer Research*, **2005**, 65, 1619-26	10.1	199
13	An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. *Cancer Research*, **2005**, 65, 4031-40	10.1	178
12	Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. *Clinical Cancer Research*, **2005**, 11, 3587-96	12.9	126

11	Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. *Development (Cambridge)*, **2004**, 131, 4213-24	6.6	182
10	Differential requirement for ptf1a in endocrine and exocrine lineages of developing zebrafish pancreas. *Developmental Biology*, **2004**, 270, 474-86	3.1	63
9	Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence. *American Journal of Surgical Pathology*, **2004**, 28, 1184-92	6.7	79
8	An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. *American Journal of Surgical Pathology*, **2004**, 28, 977-87	6.7	836
7	Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. *Pathology*, **2003**, 35, 14-24	1.6	6
6	Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. *Pathology*, **2003**, 35, 14-24	1.6	38
5	DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. *Journal of Clinical Oncology*, **2002**, 20, 4531-42	2.2	139
4	Endocrine cells of transitional mucosa adjacent to colonic adenocarcinoma. *ANZ Journal of Surgery*, **1995**, 65, 334-8	1	
3	Molecular profiling and therapeutic decision-making: the promise of personalized medicine929-935		
2	Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer		2
1	Tumor mutational landscape is a record of the pre-malignant state		8